Diagnosis and Treatment of Early Stage Testicular Cancer

Publication Date: September 14, 2023
Last Updated: September 18, 2023

Guideline Statements

Initial Management

Diagnosis and Initial Consultation

1. A solid mass in the testis identified by physical exam or imaging should be managed as a malignant neoplasm until proven otherwise. (Clinical Principle, )
322859
2. In a man with a solid mass in the testis suspicious for malignant neoplasm, serum tumor markers (AFP, hCG, and LDH) should be drawn and measured prior to any treatment, including orchiectomy. (Moderate, C)
322859
3. Prior to definitive management, patients should be counseled about the risks of hypogonadism and infertility. (Moderate, C)
322859
and should be offered sperm banking, when appropriate. In patients without a normal contralateral testis or with known subfertility, this should be considered prior to orchiectomy.
(Clinical Principle, )
322859
4. Scrotal ultrasound with Doppler should be obtained in patients with a unilateral or bilateral scrotal mass suspicious for neoplasm. (Strong, B)
322859
5. Testicular microlithiasis in the absence of solid mass and risk factors for developing a GCT does not confer an increased risk of malignant neoplasm and does not require further evaluation. (Moderate, C)
322859
6. Patients with normal serum tumor markers (hCG and AFP) and indeterminate findings on physical exam or testicular ultrasound for testicular neoplasm should undergo repeat imaging in six to eight weeks. (Clinical Principle, )
322859
7. MRI should not be used in the initial evaluation and diagnosis of a testicular lesion suspicious for neoplasm. (Moderate, C)
322859

Orchiectomy

8. Patients with a testicular lesion suspicious for malignant neoplasm and a normal contralateral testis should undergo a radical inguinal orchiectomy. Testis-sparing surgery is not recommended. Transscrotal orchiectomy is discouraged. (Strong, B)
322859
9. Testicular prosthesis should be discussed prior to orchiectomy. (Expert Opinion, )
322859
10. Patients who have undergone scrotal orchiectomy for malignant neoplasm should be counseled regarding the increased risk of local recurrence and may rarely be considered for adjunctive therapy (excision of scrotal scar or radiotherapy) for local control. (Moderate, C)
322859

Testis-Sparing Surgery

11a. TSS through an inguinal incision may be offered as an alternative to radical inguinal orchiectomy in highly selected patients wishing to preserve gonadal function with masses <2cm and
(1) equivocal ultrasound/physical exam findings and negative tumor markers (hCG and AFP),
(2) congenital, acquired or functionally solitary testis, or
(3) bilateral synchronous tumors.
(Conditional, C)
322859
11b. Patients considering TSS should be counseled regarding:
(1) higher risk of local recurrence,
(2) need for monitoring with physical examination and ultrasound,
(3) role of adjuvant radiotherapy to the testicle to reduce local recurrence,
(4) impact of radiotherapy on sperm and testosterone production, and
(5) the risk of testicular atrophy and need for testosterone replacement therapy, and/or subfertility/infertility.
(Moderate, C)
322859
11c. When TSS is performed, in addition to the suspicious mass, multiple biopsies of the ipsilateral testicle normal parenchyma should be obtained for evaluation by an experienced genitourinary pathologist. (Moderate, C)
322859

GCNIS Counseling and Management

12. Clinicians should inform patients with a history of GCT or GCNIS of risks of a second primary tumor while rare is significantly increased in the contralateral testis. (Moderate, B)
322859
13a. In patients with GCNIS on testis biopsy or malignant neoplasm after TSS, clinicians should inform patients of the risks/benefits of surveillance, radiation, and orchiectomy. (Moderate, C)
322859
13b. Clinicians should recommend surveillance in patients with GCNIS or malignant neoplasm after TSS who prioritize preservation of fertility and testicular androgen production. (Moderate, C)
322859
13c. Clinicians should recommend testicular radiation (18-20 Gy) or orchiectomy in patients with GCNIS or malignant neoplasm after TSS who prioritize reduction of cancer risk taking into consideration that radiation reduces the risk of hypogonadism compared to orchiectomy. (Moderate, C)
322859

Staging

Serum Tumor Markers

14. Nadir serum tumor markers (AFP, hCG, and LDH) should be repeated at appropriate T1/2 time intervals after orchiectomy for staging and risk stratification. (Moderate, B)
322859
15. For patients with elevated AFP or hCG post-orchiectomy, clinicians should monitor serum tumor markers to establish nadir levels before treatment only if marker nadir levels would influence treatment. (Clinical Principle, )
322859
16. For patients with metastatic GCT (Stage IIC or III) requiring chemotherapy, clinicians must base chemotherapy regimen and number of cycles on the IGCCCG risk stratification. IGCCCG risk stratification is based on nadir serum tumor marker (hCG, AFP and LDH) levels obtained prior to the initiation of chemotherapy, staging imaging studies, and tumor histology following radical orchiectomy. (Strong, A)
322859
Any post-pubertal male, regardless of age, should be treated according to adult treatment guidelines. (Moderate, B)
322859
17. For patients in whom serum tumor marker (AFP and hCG) levels are borderline elevated (within 3x upper limit of normal) post-orchiectomy, a rising trend should be confirmed before management decisions are made as false-positive elevations may occur. (Clinical Principle, )
322859

Imaging

18. In patients with newly diagnosed GCT, clinicians must obtain a CT scan of the abdomen and pelvis with IV contrast or MRI if CT is contraindicated. (Strong, B)
322859
19a. In patients with newly diagnosed GCT, clinicians must obtain chest imaging. (Clinical Principle, )
322859
19b. In the presence of elevated and rising post-orchiectomy markers (hCG and AFP) or evidence of metastases on abdominal/pelvic imaging, chest x-ray or physical exam, a CT chest should be obtained. (Strong, C)
322859
19c. In patients with clinical stage I seminoma, clinicians should preferentially obtain a chest x-ray over a CT scan. (Moderate, B)
322859
19d. In patients with NSGCT, clinicians may preferentially obtain a CT scan of the chest over a chest x-ray and should prioritize CT chest for those patients recommended to receive adjuvant therapy. (Conditional, C)
322859
20. In patients with newly diagnosed GCT, clinicians should not obtain a PET scan for staging. (Strong, B)
322859
21. Patients should be assigned a TNM-s category to guide management decisions. (Strong, B)
322859

Management

Principles of Management

22. Management decisions should be based on imaging obtained within the preceding 4 weeks and serum tumor markers (hCG and AFP) within the preceding 10 days. (Expert Opinion, )
322859
23. Management decisions should be made in a multidisciplinary setting involving experienced clinicians in urology, medical oncology, radiation oncology, pathology, and radiology. (Clinical Principle, )
322859
24. Expert review of pathologic specimens should be considered in clinical scenarios where treatment decisions will be impacted. (Moderate, C)
322859
25. In patients with normal serum tumor markers (hCG and AFP) and equivocal imaging findings for metastasis, clinicians may consider repeat imaging in six to eight weeks to clarify the extent of disease prior to making a treatment recommendation. (Clinical Principle, )
322859

Seminoma Management – Surveillance/RPLND/Chemotherapy/Radiation

26. Clinicians should recommend surveillance after orchiectomy for patients with stage I seminoma. Adjuvant radiotherapy and carboplatin-based chemotherapy are less preferred alternatives. (Strong, B)
322859
For patients with IIB seminoma with a lymph node >3 cm, chemotherapy is recommended. (Moderate, B)
322859
27a. For patients with stage IIA or IIB seminoma with a lymph node ≤3cm, clinicians should recommend radiation therapy (RT)or multi-agent cisplatin-based chemotherapy based on shared decision-making. (Moderate, B)
322859
27b. For patients with stage IIA or IIB seminoma with a lymph node ≤3cm who wish to avoid the long-term toxicities associated with chemotherapy or RT, RPLND may be offered as an appropriate and effective treatment option. (Moderate, B)
322859
27c. For patients with IIB seminoma with a lymph node >3 cm, chemotherapy is recommended. (Moderate, B)
322859

Non Seminoma Management – Surveillance/RPLND/Chemotherapy/Radiation

28. Clinicians should recommend risk-appropriate, multi-agent chemotherapy for patients with NSGCT with elevated and rising post-orchiectomy serum AFP or hCG (i.e. stage TanyN1-2S1). (Strong, B)
322859
29. Clinicians should recommend surveillance for patients with stage IA NSGCT. RPLND or one cycle of bleomycin, etoposide, and cisplatin chemotherapy are effective and appropriate alternative treatment options for patients who decline surveillance or are at risk for non-compliance. (Moderate, B)
322859
30. For patients with stage IB NSGCT, clinicians should recommend surveillance, RPLND, or one or two cycles of bleomycin, etoposide, and cisplatin chemotherapy based on shared decision-making. (Strong, B)
322859
31. Patients with stage I NSGCT and any secondary somatic malignancy (also known as teratoma with malignant transformation) in the primary tumor at orchiectomy should undergo RPLND. (Expert Opinion, )
322859
32. Clinicians should recommend RPLND or chemotherapy for patients with stage IIA NSGCT with normal post-orchiectomy serum (S0) AFP and hCG. (Moderate, B)
322859
33. In patients with clinical stage IIB NSGCT and normal post-orchiectomy serum AFP and hCG, clinicians should recommend risk-appropriate, multi-agent chemotherapy. (Moderate, B)
322859
Clinicians may offer RPLND as an alternative to chemotherapy to select patients with clinical stage IIB NSGCT with normal post-orchiectomy serum AFP and hCG. (Conditional, C)
322859
34. Among patients who are candidates for RPLND, it is recommended clinicians consider referral to an experienced surgeon at a high-volume center. (Moderate, C)
322859
35. Surgeons with experience in the management of GCT and expertise in minimally invasive surgery may offer a minimally-invasive RPLND, acknowledging the lack of long-term data on oncologic outcomes. (Expert Opinion, )
322859
36. Primary RPLND should be performed with curative intent in all patients. RPLND should be performed with adherence to the following anatomical principles, regardless of the intent to administer adjuvant chemotherapy. These principles are applied to both open and minimally-invasive approaches. (Moderate, B)
  • A full bilateral template dissection should be performed in patients with suspicious lymph nodes based on CT imaging or intraoperative assessment and in those with somatic-type malignancy in the primary tumor.
  • A full bilateral template or modified template dissection may be performed in patients with clinically negative lymph nodes.
  • A right modified template dissection may omit the para-aortic lymph nodes below the inferior mesenteric artery. Omission of para-aortic lymph nodes above the inferior mesenteric artery is controversial.
  • A left modified template dissection may omit paracaval, precaval, and retrocaval lymph nodes. Omission of interaortocaval lymph nodes is controversial.
  • Nerve-sparing should be offered in select patients desiring preservation of ejaculatory function.
  • Nerve-sparing attempts should not compromise the quality of the lymph node dissection.
  • A complete retroaortic and/or retrocaval lymph node dissection with division of lumbar vessels should be performed when within the planned template.
  • The ipsilateral gonadal vessels should be removed in all patients.
  • The cephalad extent of the dissection is the crus of the diaphragm to the level of the renal arteries. The caudad extent of disease is the crossing of the ureter over the ipsilateral common iliac artery.
322859
37. After primary RPLND, clinicians should recommend surveillance or adjuvant chemotherapy in patients with NSGCT who have pathological stage II disease that is not pure teratomahistology. For patients with pN1 and/or pN1-3 pure teratoma, surveillance is preferred. For patients with pN2-3 at RPLND, multi-agent cisplatin-based chemotherapy is preferred. (Moderate, B)
322859

Surveillance for Stage I Testicular Cancer

38. For patients with clinical stage I seminoma choosing surveillance, clinicians should obtain a history and physical examination and perform cross-sectional imaging of the abdomen with or without the pelvis every 6 months for the first 2 years, and then every 6-12 months in years 3-5. Routine surveillance imaging of the chest and serum tumor marker assessment can be obtained as clinically indicated. (Strong, B)
322859
39. In patients with stage I NSGCT undergoing surveillance after orchiectomy, clinicians should perform a physical examination and obtain serum tumor markers (AFP, hCG +/- LDH) every 2-3 months in year 1, every 2-4 months in year 2, every 4-6 months in year 3, and every 6-12 months for years 4 and 5. (Moderate, C)
322859
40. In patients with stage I NSGCT undergoing surveillance after orchiectomy, radiologic assessment (chest x-ray and imaging of the abdomen with or without the pelvis) should be obtained every 3-6 months in year 1 starting at 3 months, every 4-12 months in year 2, once in year 3, and once in year 4 or 5. (Moderate, B)
322859
Men at higher risk of relapse (e.g., lymphovascular invasion) should be imaged with shorter intervals. (Expert Opinion, )
322859
41. Patients who relapse on surveillance should be fully restaged and treated based on their TNM-s status. (Moderate, C)
322859
42. Clinicians should inform patients with stage I GCT on surveillance of the <1% risk of late relapse after 5 years. (Moderate, B)
322859
Annual serologic and radiographic assessment may be performed thereafter as indicated based upon clinical concerns. (Clinical Principle, )
322859

Additional Survivorship

43. Clinicians should refer patients to a survivorship clinic appreciating the long-term risks and potential sequelae of prior treatment among patients with GCT, with the integration of screening and monitoring for potential medical issues thatmay arise including the following:
  • Patients with a history of GCT should be monitoredfor signs and symptoms of hypogonadism. If present, serum AM testosterone and luteinizing hormone levels should be measured.
  • Patients with a history of GCT whose treatment has included RT, chemotherapy, or both should be advised of the elevated risk of cardiovascular disease and should establish regular care with a primary care physician so that modifiable risk factors for cardiovascular disease (e.g., diet, exercise, smoking, serum lipid levels, blood pressure, serum glucose) can be monitored.
  • Patients with a history of GCT whose treatment has included RT, chemotherapy, or both should be advised of the elevated risk of secondary malignancy and should establish regular care with a primary care physician for appropriate health care maintenance and cancer screening as deemed appropriate.
(Expert Opinion, )
322859

Recommendation Grading

Overview

Title

Diagnosis and Treatment of Early Stage Testicular Cancer

Authoring Organization

Publication Month/Year

September 14, 2023

Last Updated Month/Year

February 14, 2024

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Document Objectives

This guideline seeks to improve clinicians' ability to evaluate and treat patients with early-stage testicular cancer based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.

Inclusion Criteria

Male, Adolescent, Adult, Child, Older adult

Health Care Settings

Ambulatory, Hospital, Outpatient

Intended Users

Nurse, nurse practitioner, physician, physician assistant

Scope

Diagnosis, Treatment, Management

Diseases/Conditions (MeSH)

D013736 - Testicular Neoplasms

Keywords

testis cancer, Early Stage Testicular Cancer, male cancer

Source Citation

Stephenson A, Bass EB, Bixler BR, Daneshmand S, Kirkby E, Marianes A, Pierorazio PM, Sharma R, Spiess PE. Diagnosis and Treatment of Early-Stage Testicular Cancer: AUA Guideline Amendment 2023. J Urol. 2023 Sep 14:101097JU0000000000003694. doi: 10.1097/JU.0000000000003694. Epub ahead of print. PMID: 37707243.

Methodology

Number of Source Documents
240
Literature Search Start Date
January 1, 1980
Literature Search End Date
August 1, 2018